Thermo Fisher Scientific Inc. $TMO Shares Sold by Capital Fund Management S.A.

Key Points

• Capital Fund Management S.A. has reduced its stake in Thermo Fisher Scientific Inc. by 70.9%, now holding 21,759 shares worth approximately $10.8 million.
• Thermo Fisher recently reported $5.36 EPS for the quarter, exceeding the consensus estimate of $5.22, and has set guidance for Q3 2025 EPS between $5.460-$5.510.
• The company's quarterly dividend of $0.43 is set to be paid on October 15th, with an annualized payout of $1.72 and a yield of 0.4%.

Capital Fund Management S.A. reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 70.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,759 shares of the medical research company's stock after selling 53,065 shares during the period. Capital Fund Management S.A.'s holdings in Thermo Fisher Scientific were worth $10,827,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of Thermo Fisher Scientific by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after purchasing an additional 230,382 shares during the last quarter. Northern Trust Corp lifted its stake in Thermo Fisher Scientific by 13.2% in the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after acquiring an additional 455,004 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Thermo Fisher Scientific by 4.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after buying an additional 115,463 shares during the period. Pictet Asset Management Holding SA increased its holdings in Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock valued at $1,432,816,000 after buying an additional 193,378 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Thermo Fisher Scientific by 11.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,420,949 shares of the medical research company's stock worth $1,259,450,000 after purchasing an additional 257,462 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,896 shares of company stock worth $13,603,438. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 0.8%

Shares of NYSE TMO traded down $3.74 during midday trading on Wednesday, hitting $484.75. The stock had a trading volume of 338,716 shares, compared to its average volume of 2,455,361. The business's 50 day moving average is $446.71 and its 200-day moving average is $455.47. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market cap of $183.05 billion, a P/E ratio of 28.01, a PEG ratio of 2.62 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is 9.95%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Argus dropped their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Robert W. Baird increased their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating on the stock. Barclays upped their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research note on Thursday, July 24th. Finally, Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.